OncoMatch/Clinical Trials/NCT05669586
Organoids Predict Therapeutic Response in Patients With Multi-line Drug-resistant Lung Cancer
Is NCT05669586 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Antitumor therapy guided by organoid drug sensitivity test for lung cancer.
Treatment: Antitumor therapy guided by organoid drug sensitivity test — This is a single-center, single-arm, open and exploratory clinical study. The purpose of this study was to evaluate the consistency and accuracy of the organogenic (PDO) model for patients with lung cancer, to predict the clinical efficacy of anticancer drugs, and to speculate and select personalized treatment regiments for patients with lung cancer who are resistant to multi-line standard therapies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Prior therapy
Must have received: multiline standard therapy
disease progression after multiline standard therapy
Cannot have received: other investigational drug
Participated in clinical trials of other drugs within four weeks.
Lab requirements
Cardiac function
No NYHA class 2 or higher heart failure, unstable angina, MI within 1 year, or clinically significant arrhythmia requiring intervention
clinical symptoms or diseases of the heart that cannot be well controlled, such as: NYHA class 2 or higher heart failure, unstable angina pectoris, myocardial infarction within 1 year, clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify